Form D · Biotechnology
Alzamend Neuro, Inc.
Tampa, FL · CIK 0001677077
Offering snapshot reported Apr 23, 2019 · SEC filing
- Reported sold
- $232K Offering amount: $2M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $999 Reported outside-investor minimum
- First sale
- Mar 4, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 23, 2019 | Initial | $231,519 | No comparison | 17 | SEC filing |
| Aug 22, 2017 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jun 22, 2016 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-337858
On 3/04/19, the Issuer sold and issued to accredited investors an aggregate of 154,346 shares of common stock at $1.50 per share, and warrants to purchase 77,173 shares, in the aggregate, at an exercise price of $3.00.
Source: Form D, filed Apr 23, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Milton C. Ault | Director |
| Milton C Ault Iii | Director |
| Kenneth S. Cragun | Executive |
| William B. Horne | Director |
| Stephan Jackman | Executive |
| Philip E. Mansour | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3802 Spectrum Blvd, Suite 112 C
Tampa, FL, 33612
Tampa, FL, 33612